Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure - Université Paris-Saclay
Article Dans Une Revue Nature Reviews Cardiology Année : 2023

Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

Résumé

Cyclic nucleotide phosphodiesterases (PDEs) modulate the neuro-hormonal regulation of cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes with different enzymatic properties and subcellular localization regulate local pools of cyclic nucleotides and specific functions. This organization is heavily perturbed during cardiac hypertrophy and heart failure (HF), which can contribute to disease progression. Clinically, PDE inhibition was once considered a promising approach to compensate for the catecholamine desensitization that accompanies HF. Although PDE3
Fichier principal
Vignette du fichier
Version HAL.pdf (3.51 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03793963 , version 1 (02-10-2022)

Identifiants

Citer

Rima Kamel, Jérôme Leroy, Grégoire Vandecasteele, Rodolphe Fischmeister. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nature Reviews Cardiology, 2023, 20, pp.90-108. ⟨10.1038/s41569-022-00756-z⟩. ⟨hal-03793963⟩
24 Consultations
67 Téléchargements

Altmetric

Partager

More